Study of the BDNF- Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal

Centre Hospitalier Esquirol1 site in 1 country180 target enrollmentMay 2014

ConditionsAlcohol Dependence

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Alcohol Dependence
Sponsor: Centre Hospitalier Esquirol
Enrollment: 180
Locations: 1
Primary Endpoint: Frequency of the Bdnf gene Val/Val, Val/Met and Met/Met phenotypes as a function of relapse
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study is complementary to the main study "Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal " NCT01491347.

The purpose of this study is to evaluate the Bdnf gene - Val66Met polymorphism in subjects with alcohol dependence according to their alcohol consumption status 6 months after withdrawal (relapse or abstinence), in relation to the presence of psychiatric co-morbidities.

Registry

clinicaltrials.gov

Start Date

May 2014

End Date

April 2016

Last Updated

9 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Centre Hospitalier Esquirol

Responsible Party

Principal Investigator

Philippe Nubukpo

MD, PhD

Centre Hospitalier Esquirol

Eligibility Criteria

Inclusion Criteria

•participation to the study "BDNF serum levels evolution during 6 months after alcohol withdrawal" (main study)
•criteria from the main study

Exclusion Criteria

•criteria from the main study
•released or out from the main study before the follow-up at 4 months after withdrawal

Outcomes

Primary Outcomes

Frequency of the Bdnf gene Val/Val, Val/Met and Met/Met phenotypes as a function of relapse

Time Frame: at the time of inclusion

Secondary Outcomes

serum BDNF levels variations between inclusion and 6 months later (or 4 months if the participants does not come for the 4 months-follow-up).(6 months after alcohol withdrawal)
presence of a psychiatric co-morbidity at 6 months after withdrawal (major depression, schizophrenia, anxiety disorder)(6 month after alcohol withdrawal)
existence of a psychiatric co-morbidity at the inclusion (major depression, schizophrenia, anxiety disorder)(at the time of inclusion)